Use of the thyrocyte sodium iodide symporter as the basis for a perchlorate cell-based assay.

Perchlorates are strong oxidants widely employed in military and civilian energetic materials and recently have been scrutinized as persistent environmental pollutants. The perchlorate anion, ClO(4)(-), is a well-known and potent competitive inhibitor of iodide transport by the sodium iodide symporter (NIS) expressed in the basolateral membranes of thyroid follicular cells (thyrocytes). Iodide uptake by thyroid follicular cells is rapid and reproducible. The competitive radiotransporter assay in this study shows promise as a rapid and convenient method to assay for ClO(4)(-) in water samples at the nM level. This work describes the initial efforts to define the assay conditions that enhance NIS selectivity for ClO(4)(-). Experiments of 10 min co-incubation of ClO(4)(-) and (125)I(-) demonstrate a more significant effect on (125)I(-) transport, with a quantifiable ClO(4)(-) concentration range of 50 nM (5 ppb) to 2 microM (200 ppb), and IC(50) of 180 nM (18 ppb), nearly three-fold lower than previous reports. Since the IC(50) in our assay for other known competitor anions (SCN(-), ClO(3)(-), NO(3)(-)) remains unchanged from previous research, the increased sensitivity for ClO(4)(-) also produces a three-fold enhancement in selectivity. In addition to the possible applicability of the thyrocyte to the development of a cellular perchlorate biosensor, we propose that the high affinity of the NIS for ClO(4)(-) also creates the potential for exploiting this membrane protein as a selective, sensitive, and broadly applicable biomechanical mechanism for controlled movement and concentration of perchlorate.

Conquering the third ventricular chamber.

Surgery within the third ventricle was a special challenge early in the conception of the discipline of neurosurgery due to a lack of diagnostic methods and difficulty in reaching and removing lesions affecting this vital region. Walter Dandy and Harvey Cushing performed pioneering approaches of the third ventricular region. The authors have reviewed the previously undisclosed efforts of Cushing to approach the third ventricle through a direct review of his available patient records at the Cushing Brain Tumor Registry. The authors compare these efforts to those of Dandy published in Dandy's pioneering work Benign Tumors in the Third Ventricle of the Brain: Diagnosis and Treatment. Based on the review of these records, the authors attempt to examine the foundations of surgery within the third ventricle.

Mutational replacement of Leu-293 in the class C Enterobacter cloacae P99 beta-lactamase confers increased MIC of cefepime.

The class C beta-lactamase from Enterobacter cloacae P99 confers resistance to a wide range of broad-spectrum beta-lactams but not to the newer cephalosporin cefepime. Using PCR mutagenesis of the E. cloacae P99 ampC gene, we obtained a Leu-293-Pro mutant of the P99 beta-lactamase conferring a higher MIC of cefepime (MIC, 8 microg/ml, compared with 0.5 microg/ml conferred by the wild-type enzyme). In addition, the mutant enzyme produced higher resistance to ceftazidime but not to the other beta-lactams tested. Mutants with 15 other replacements of Leu-293 were prepared by site-directed random mutagenesis. None of these mutant enzymes conferred MICs of cefepime higher than that conferred by Leu-293-Pro. We determined the kinetic parameters of the purified E. cloacae P99 beta-lactamase and the Leu-293-Pro mutant enzyme. The catalytic efficiencies (k(cat)/K(m)) of the Leu-293-Pro mutant beta-lactamase for cefepime and ceftazidime were increased relative to the respective catalytic efficiencies of the wild-type P99 beta-lactamase. These differences likely contribute to the higher MICs of cefepime and ceftazidime conferred by this mutant beta-lactamase.